

Republic of the Philippines Department of Health FOOD AND DRUG ADMINISTRATION



FDA ADVISORY No. 2018-138 11 1 APR 2018

TO:

ALL HEALTHCARE PROFESSIONALS AND THE **GENERAL PUBLIC**

SUBJECT:

Public Health Warning Against the Purchase and Use of the Verified Counterfeit Drug Product Purified Chick Embryo Cell Rabies Vaccine (Inactivated) (Rabipur) 2.5 I.U./mL Lyophilized Powder For Injection (ID/IM)

The Food and Drug Administration (FDA) advises the public against the purchase and use of the verified counterfeit drug product Purified Chick Embryo Cell Rabies Vaccine (Inactivated) (Rabipur) 2.5 I.U./mL Lyophilized Powder For Injection (ID/IM):



Figure 1. Verified counterfeit sample of Rabipur Vaccine





The FDA, together with the Marketing Authorization Holder (MAH), GlaxoSmithKline Philippines, Inc., have verified that the abovementioned sample drug product is counterfeit. The comparisons of the collected product and the registered and authentic one are as follows:



Secondary packaging: Box (Front)

Pre-printed text font size and colour of carton are different

Note: (Authentic Rabipur) Two stickers were affixed on the front side of carton:

(1) Rx sticker

(2) Brand owners details:

- "Manufactured by: Chiron Behring Vaccines Pte Ltd. 3502 G. I.D. C. Industrial Estate, Ankleshwar 393 002, India"
- "Imported by: Novartis Healthcare Inc. Asian Reinsurance Building, Salcedo corner Gamboa Streets, Legaspi Village, Makati "New Marketlink Pharm'l. Corp. – 2291 Don Chino Roces Avenue, Makati City" "Distributed by: Metro Drug Inc. – Meralco Ave., Bagumbayan, Taguig City"



Secondary packaging: Box (Back)

- Overprinted text matter font and its size are different
- 2D barcode printing pattern is different

Pre-printed text matter font size is different

Sterile Water for Injection (SWFI) Ampoule label

sample of SWFI ampoule has Batch No. S-164



AUTHENTIC

COUNTERFEIT

Imi Water for injecting imi Agua para injusting para important in Eau out pressure in Vaccine po/DRUC /DD/US83 Wlate: Mfd./Preplations injectables | S-164 | 112011 |

S-164 | 112011 |

S-164 | 112011 |

A112(1211A)W97

Retention sample has SWFI Batch No. K-388, however the complaint



All healthcare professionals and the general public are hereby warned as to the availability of this counterfeit drug product in the market which pose potential danger or injury to consumers. Consumers are also reminded to purchase drug products only from FDA-licensed establishments.

Likewise, all establishments and outlets are hereby warned against selling and/or dispensing this verified counterfeit drug product with the foregoing features. The importation, selling or offering for sale of such is in direct violation of Republic Act No. 9711, or the Food and Drug Administration Act of 2009, and Republic Act No. 8203, or the Special Law on Counterfeit Drugs, therefore a penalty shall be imposed.

All Local Government Units (LGUs) and Law Enforcement Agencies (LEAs) are requested to ensure that this counterfeit product is not sold or made available in their localities or areas of jurisdiction.

For more information and inquiries, please e-mail us at info@fda.gov.ph. To report continuous sale or distribution of unregistered health products, kindly e-mail us via report@fda.gov.ph, or through the online reporting facility, eReport, at www.fda.gov.ph/ereport. You may also call the Center for Drug Regulation and Research at telephone number (02)809-5596. For any suspected adverse drug reaction (ADR), report immediately to FDA through this link: www.fda.gov.ph/adr-report-new and fill out all the required fields.

Dissemination of the information to all concerned is requested.

NELA CHARADE G. PUNO, RPh Director General

